Skip to content

Zander Therapeutics, Inc

company.status.inactive

CIK 1718644fmd_1DMWD72Q0CCN8Z8SNQVHMR4XGRManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jul 01, 2016 to Sep 30, 2019, 10 periods

Income Statement · Annual · Millions · USD
Line itemFY2017FY2018FY2019
Realized investment gains (losses)––2
Research and development–21
Selling, general and administrative–01
Operating income–(2)(2)
Interest expense––0
Other non-operating income (expense)–(0)2
Net income(0)(2)0
Net income to common shareholders–(2)0